The Committee on Medical Affairs proposed the following amendment (427R001.SP.DBV):

Amend the bill, as and if amended, on page 2, by striking lines 23 through 24 and inserting:

/ (C) A renal drug manufacturer may deliver a legend dialysate drug comprised of dextrose or icodextrin or a device to a patient of an RDF if the following criteria are met: /